+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Treatment of human breast cancer cells with nitric oxide mimetics prevents acquisition of hypoxia-induced resistance to doxorubicin



Treatment of human breast cancer cells with nitric oxide mimetics prevents acquisition of hypoxia-induced resistance to doxorubicin



Proceedings of the American Association for Cancer Research Annual Meeting 42: 814-815




(PDF emailed within 1 workday: $29.90)

Accession: 035982083

Download citation: RISBibTeXText


Related references

Differential effects of doxorubicin and docetaxel on nitric oxide production and inducible nitric oxide synthase expression in MCF-7 human breast cancer cells. Oncology Research 14(7-8): 381-386, 2004

Nitric oxide attenuates resistance to doxorubicin in three-dimensional aggregates of human breast carcinoma cells. Breast Cancer Research and Treatment 96(2): 169-176, 2005

Resveratrol reduces the hypoxia-induced resistance to doxorubicin in breast cancer cells. Journal of Nutritional Science and Vitaminology 60(2): 122-128, 2015

Multicellular resistance to doxorubicin is attenuated by nitric oxide mimetics. Proceedings of the American Association for Cancer Research Annual Meeting 44: 1304, 2003

Treatment schedule and estrogen receptor-status influence acquisition of doxorubicin resistance in breast cancer cells. European Journal of Pharmaceutical Sciences 104: 424-433, 2017

Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Research 65(2): 516-525, 2005

Anterior gradient 2 is a binding stabilizer of hypoxia inducible factor-1α that enhances CoCl2 -induced doxorubicin resistance in breast cancer cells. Cancer Science 106(8): 1041-1049, 2015

Paeoniflorin prevents hypoxia-induced epithelial-mesenchymal transition in human breast cancer cells. Oncotargets and Therapy 9: 2511-2518, 2016

Atorvastatin prevents hypoxia-induced inhibition of endothelial nitric oxide synthase expression but does not affect heme oxygenase-1 in human microvascular endothelial cells. Atherosclerosis 187(1): 26-30, 2006

Differential drug resistance acquisition to doxorubicin and paclitaxel in breast cancer cells. Cancer Cell International 14(1): 142, 2015

Differential drug resistance acquisition to doxorubicin and paclitaxel in breast cancer cells. Cancer Cell International 14(1): 142, 2015

Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer. Journal of Experimental and Clinical Cancer Research 37(1): 286, 2018

Mechanism of phorbol ester-induced potentiation of doxorubicin resistance in human breast cancer MCF-7/Dox cells. Proceedings of the American Association for Cancer Research Annual Meeting 34(0): 311, 1993

JS-K, a GST-activated nitric oxide donor prodrug, enhances chemo-sensitivity in renal carcinoma cells and prevents cardiac myocytes toxicity induced by Doxorubicin. Cancer ChemoTherapy and Pharmacology 80(2): 275-286, 2017

Nanometronomic treatment of 4T1 breast cancer with nanocaged doxorubicin prevents drug resistance and circumvents cardiotoxicity. Oncotarget 8(5): 8383-8396, 2017